RT Journal Article
SR Electronic
T1 Quantifying impacts of the COVID-19 pandemic through life expectancy losses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.02.21252772
DO 10.1101/2021.03.02.21252772
A1 Aburto, José Manuel
A1 Schöley, Jonas
A1 Zhang, Luyin
A1 Kashnitsky, Ilya
A1 Rahal, Charles
A1 Missov, Trifon I.
A1 Mills, Melinda C.
A1 Dowd, Jennifer B.
A1 Kashyap, Ridhi
YR 2021
UL http://medrxiv.org/content/early/2021/03/07/2021.03.02.21252772.abstract
AB Increasing life expectancy at birth, a widely-used indicator of population health and mortality, is considered a policy goal in every country. Measures of excess deaths suggest the COVID-19 pandemic substantially increased mortality in 2020 in many countries (Karlinsky and Kobak, 2021). However, because of variations in the age patterns and magnitudes of excess deaths across countries, comparing the mortality impacts of the pandemic is difficult (Aburto et al., 2021; Pifarré i Arolas et al., 2021). Life expectancy overcomes these limitations while providing a clear picture of the toll of the pandemic on mortality (Goldman and Lord, 1986; Aburto et al., 2020). Here we show that the COVID-19 pandemic halted improvements in longevity and progress mortality reductions at older ages in 2020. Life expectancy at birth declined from 2019 to 2020 in 25 out of 27 countries for which high-quality vital statistics are presently available, including most European countries, Chile and the USA. Males in the USA and Bulgaria experienced the largest losses in life expectancy at birth during 2020 (2.1 and 1.6 years respectively), but staggering reductions of more than an entire year were documented in eleven countries for males, and eight among females; a magnitude of loss not witnessed since WW-II in many countries. Reductions were mostly attributable to increased mortality above age 60 and to official COVID-19 deaths.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding is gratefully acknowledged from the British Academy's Newton International Fellowship grant NIFBA19/190679 (JMA, RK), a Rockwool Foundation's Excess Deaths grant (JMA, JS, TIM, IK), a Leverhulme Trust Large Centre Grant (JMA, LZ, RK, CR, JBD and MCM), Nuffield College (JM, RK, CR, JBD, MCM), John Fell Fund grant 0009182 (JMA, RK, CR, JBD, MCM) and European Research Council grant 835079 (MCM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe replication files for this paper including customised functions in the statistics environment R are available on Zenodo, a general-purpose open-access repository developed under the European OpenAIRE program and operated by CERN (10.5281/zenodo.4556982). https://github.com/OxfordDemSci/ex2020